Literature DB >> 11507036

A novel human cell culture model for the study of familial prostate cancer.

Y Yasunaga1, K Nakamura, C M Ewing, W B Isaacs, B Hukku, J S Rhim.   

Abstract

Research into molecular and genetic mechanisms underlying familial prostate cancer would be greatly advanced by in vitro models of prostate tumor cells representing primary tumors. We have successfully established an immortalized human prostate epithelial cell culture derived from primary tumors of familial prostate cancer patients with telomerase. The actively proliferating early-passaged 957E cells were transduced through infection with a retrovirus expressing the human telomerase catalytic subunit, human telomerase reverse transcriptase (hTERT). A high level of telomerase activity was detected in 957E/hTERT cells, but not in 957E cells. 957E/hTERT cells are currently growing well at passage 40, whereas 957E cells senesced at passage 5. 957E/hTERT cells exhibit epithelial morphology. Expression of an androgen-regulated prostate specific homeobox gene NKX3.1 and an epithelial cell-specific cytokeratin 8, but not prostate specific antigen or androgen receptor, was detected in 957E/hTERT cells. Prostatic stem cell antigen and p16 were also expressed in this line. 957E/hTERT cells showed growth inhibition when exposed to retinoic acid and transforming growth factor beta1, potent inhibitors of prostate epithelial cell growth. Chromosome analysis showed that the 957E/hTERT cell line (passage 10) was near diploid human male (XY), with most chromosome counts in the 44-46 range. However, there was random loss of chromosomes 8, 13, X, Y, and alteration in chromosome 4q. The late passage 957E/hTERT cell line (passage 32) was karyologically similar to the early passage 957E/hTERT cell line (passage 10) and also had the same alteration of 4q observed in the early passage 957E/hTERT cell line (passage 10) as well as a trisomy of chromosome 20. The well-characterized human cancer lines derived from such patients will be useful for the identification and characterization of prostate cancer susceptibility genes. This is the first documented case of an established human prostate cancer cell line from primary tumor of a familial prostate cancer patient.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507036

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Yi Xu; Lizamma Antony; Susan L Dalrymple; John T Isaacs
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

2.  Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cells.

Authors:  Bobby Bhatia; Ming Jiang; Mahipal Suraneni; Lubna Patrawala; Mark Badeaux; Robin Schneider-Broussard; Asha S Multani; Collene R Jeter; Tammy Calhoun-Davis; Limei Hu; Jianhua Hu; Spiridon Tsavachidis; Wei Zhang; Sandy Chang; Simon W Hayward; Dean G Tang
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157

3.  Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient.

Authors:  Shaniece Theodore; Starlette Sharp; Jianjun Zhou; Timothy Turner; Hongzhen Li; Jun Miki; Youngmi Ji; Vyomesh Patel; Clayton Yates; Johng S Rhim
Journal:  Int J Oncol       Date:  2010-12       Impact factor: 5.650

4.  Low p16INK4a Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone.

Authors:  Mindy Kim Graham; Lorenzo Principessa; Lizamma Antony; Alan K Meeker; John T Isaacs
Journal:  Prostate       Date:  2016-11-08       Impact factor: 4.104

5.  Vitamin D regulates prostate cell metabolism via genomic and non-genomic mitochondrial redox-dependent mechanisms.

Authors:  Chuck C Blajszczak; Larisa Nonn
Journal:  J Steroid Biochem Mol Biol       Date:  2019-09-28       Impact factor: 4.292

6.  Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.

Authors:  Michel D Wissing; Janet Mendonca; Madeleine S Q Kortenhorst; Nadine S Kaelber; Matthew Gonzalez; Eunice Kim; Hans Hammers; Paul J van Diest; Michael A Carducci; Sushant K Kachhap
Journal:  FASEB J       Date:  2013-07-24       Impact factor: 5.191

7.  Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.

Authors:  Wennuan Liu; Chunmei Carol Xie; Yi Zhu; Tao Li; Jishan Sun; Yu Cheng; Charles M Ewing; Sue Dalrymple; Aubrey R Turner; Jielin Sun; John T Isaacs; Bao-Li Chang; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

8.  Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer.

Authors:  Deborah L Burkhart; Katherine L Morel; Kristine M Wadosky; David P Labbé; Phillip M Galbo; Zafardjan Dalimov; Bo Xu; Massimo Loda; Leigh Ellis
Journal:  Cancer Prev Res (Phila)       Date:  2020-09-11

9.  Evidence for the isolation, growth, and characterization of malignant cells in primary cultures of human tumors.

Authors:  Robert L Ochs; Jeffrey Fensterer; N Paul Ohori; Alan Wells; Michael Gabrin; Lisa D George; Paul Kornblith
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jan-Feb       Impact factor: 2.416

10.  Decoding the fine-scale structure of a breast cancer genome and transcriptome.

Authors:  Stanislav Volik; Benjamin J Raphael; Guiqing Huang; Michael R Stratton; Graham Bignel; John Murnane; John H Brebner; Krystyna Bajsarowicz; Pamela L Paris; Quanzhou Tao; David Kowbel; Anna Lapuk; Dmitri A Shagin; Irina A Shagina; Joe W Gray; Jan-Fang Cheng; Pieter J de Jong; Pavel Pevzner; Colin Collins
Journal:  Genome Res       Date:  2006-02-03       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.